Glaxo Reports Double-Digit Growth In Q3 Pharma, Vaccine Sales, Updates FY21 Guidance

  • GlaxoSmithKline Plc's GSK turnover was £9.07 billion in Q3, up 5% Y/Y (actual exchange rate AER), 10% (constant exchange rate CER).
  • Pharmaceuticals sales reached £4.4 billion, up 5% AER, 10% CER. Sales of Xevudy, the COVID-19 monoclonal antibody treatment, and contributed approximately 3 percentage points to total Pharmaceuticals growth.
  • COVID-19 solutions sales £209 million including Xevudy £114 million and pandemic adjuvant £94 million.
  • Vaccines sales grew 7% AER, 13% CER to £2.2 billion, primarily driven by higher Shingrix sales in the U.S. and Europe and pandemic adjuvant sales.
  • Vaccines turnover excluding pandemic vaccines grew 2% AER, 8% CER to £2.2 billion. 
  • Adjusted operating margin of 31.7% is 0.8 percentage points higher at AER and 1.5 percentage points higher on a CER basis than Q3 2020.
  • Adjusted EPS was 36.6p, up 3% AER, 10% CER.
  • The net cash flow from operations was £2.6 billion. The free cash outflow was £1.2 billion.
  • Outlook: GlaxoSmithKline expects the 2021 adjusted EPS outlook to decline between 2% to 4% at CER, against a previously mid-to-high single-digit decline.
  • GSK reconfirms a meaningful improvement in revenues and margins in 2022.
  • Price Action: GSK shares are up 0.31% at $40.31 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!